Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2023 was $14.5 million, representing a growth of 27% compared to $11.4 million in the first quarter of 2022 and a sequential increase of 13% from $12.8 million in the fourth quarter of 2022 [3][6] - Gross margin for the first quarter of 2023 was 72%, down from 73% in the first quarter of 2022 and up from 69% in the fourth quarter of 2022 [56] - Net loss for the first quarter of 2023 was $10.4 million, compared to a net loss of $11.5 million in the first quarter of 2022 [75] Business Line Data and Key Metrics Changes - Replacement implant revenue generated $1.2 million in the first quarter, which is a decrease from previous quarters as expected [47] - The DIXI Medical distribution partnership contributed positively to revenue, with expectations for continued growth as the business matures [10][54] - Initial implant revenue growth was driven by increased utilization of the RNS System within Comprehensive Epilepsy Centers (CECs) [22][62] Market Data and Key Metrics Changes - The company is focusing on expanding its presence in the generalized epilepsy market, which represents about 40% of drug-resistant epilepsy patients [30][73] - The company reported stable patient volumes in Epilepsy Monitoring Units (EMUs) over the past year, indicating a gradual recovery from pre-pandemic levels [53] Company Strategy and Development Direction - The company aims to increase utilization of the RNS System by expanding patient selection, managing the patient pipeline, and driving adoption with new prescribers and implanting centers [22][23] - The strategy includes leveraging the DIXI Medical product line to enhance patient identification and conversion to RNS System implants [54][62] - The company is focused on closing the treatment gap for drug-resistant epilepsy patients by educating physicians on the benefits of the RNS System [72] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for initial implants and the DIXI Medical products, while also acknowledging the challenges in replacement implant revenue [62][75] - The company expects total revenue for 2023 to range between $52 million and $54 million, an increase from the previous guidance of $50 million to $52 million [53][57] - Management highlighted the importance of the NAUTILUS study for primary generalized epilepsy and the NIH study for Lennox-Gastaut syndrome as key clinical priorities [46][73] Other Important Information - Cash and short-term investments as of March 31, 2023, were $67.6 million, with long-term borrowings totaling $53.9 million [7] - Operating expenses for the first quarter of 2023 were $18.7 million, slightly higher than $18 million in the same period of the prior year, but as a percentage of revenue, they were lower for both R&D and SG&A [25] Q&A Session Summary Question: Can you provide specifics on revenue from the three lines? - Management indicated that while replacement revenue was $1.2 million, they did not disclose specific figures for DIXI Medical and new patient revenue due to competitive reasons [33][39] Question: How is the DIXI Medical product impacting patient conversion? - Management noted that the DIXI Medical product is providing visibility into the diagnostic process, which is helping to convert patients to RNS System implants [82] Question: What is the outlook for the NAUTILUS study? - Enrollment for the NAUTILUS study is on track to be completed in the first quarter of 2024, with results expected to support a PMA supplement for generalized epilepsy [46][80]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 22-3550230 (I.R.S. Employer Iden ...

NeuroPace, Inc. (NASDAQ:NPCE) Q4 2022 Results Conference Call March 2, 2023 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group Michael Favet - President, CEO & Director Rebecca Kuhn - CFO, VP, Finance & Administration and Assistant Secretary Conference Call Participants Michael Polark - Wolfe Research Frank Takkinen - Lake Street Capital Markets Robbie Marcus - JPMorgan Vik Chopra - Wells Fargo Drew Ranieri - Morgan Stanley Operator Good afternoon, and welcome to NeuroPace's Fourth Quarter Earnin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ___________ Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) Delaware 22-3550230 (State or Other Jurisd ...

I - NEUROPACE, N O V E M B E R 2 0 2 2 Personalized, data-driven treatment for epilepsy 1 Disclaimer | 2 In addition to background and historical information, this presentation contains "forward-looking statements" based on NeuroPace's current expectations, estimates, forecasts and beliefs, including financial results for the third quarter ended September 30, 2021, information about NeuroPace's market opportunity, growth drivers and market penetration, commercial strategy, future pipeline, indication and TA ...

Neuropace, Inc. (NASDAQ:NPCE) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group Michael Favet - President, CEO & Director Rebecca Kuhn - CFO, VP, Finance & Administration and Assistant Secretary Conference Call Participants Allen Gong - JPMorgan Chase & Co. Lawrence Biegelsen - Wells Fargo Securities Operator Good day, and thank you for standing by. Welcome to the Q3 2022 NeuroPace earnings conference call. [Operator Instructions]. Please be ad ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 22-3550230 (I.R.S. Employer Identification Number) 455 N. Bernardo Av ...

NeuroPace, Inc. (NASDAQ:NPCE) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Matt Bacso - Investor Relations Mike Favet - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Robert Marcus - JPMorgan Drew Ranieri - Morgan Stanley Operator Good afternoon, and welcome to NeuroPace's Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a qu ...

I - NEUROPACE, A U G U S T 2 0 2 2 Personalized, data-driven treatment for epilepsy 1 Disclaimer | 2 In addition to background and historical information, this presentation contains "forward-looking statements" based on NeuroPace's current expectations, estimates, forecasts and beliefs, including financial results for the fourth quarter and full year ended December 31, 2021, information about NeuroPace's market opportunity, growth drivers and market penetration, commercial strategy, future pipeline, indicat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiz ...